EICHOR
● Active Not Recruiting
A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS
Condition: LOCALLY ADVANCED CERVICAL CANCERS · Sponsor: ARCAGY/ GINECO GROUP
About this study
Multicenter, open-label, randomized, seeking signal (non-comparative), Phase II aiming to assess the clinical activity of the combination relatlimab + nivolumab in locally advanced cervical cancer eligible to standard CCRT
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (30)
| ICO Paul Papin | Angers, France | — |
| Sainte-Catherine Institut du Cancer Avignon-Provence | Avignon, France | — |
| CHRU Besançon - Hôpital Jean Minjoz | Besançon, France | — |
| Institut Bergonié | Bordeaux, France | — |
| CHU de BREST - Hôpital Cavale Blanche | Brest, France | — |
| Centre François Baclesse | Caen, France | — |
| Centre Jean Perrin | Clermont-Ferrand, France | — |
| Centre Hospitalier Intercommunal de Créteil | Créteil, France | — |
| CHU de Dijon | Dijon, France | — |
| Soumya.Anane@chicreteil.fr | Dijon, France | — |
| CHRU Lille - Hôpital Jeanne de Flandre | Lille, France | — |
| Centre Oscar Lambret | Lille, France | — |
+ 18 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06715241